ClearPoint Neuro, Inc.
CLPTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ClearPoint Neuro, Inc. focuses on Medical Devices services and products. ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in. Valued at $454.3M, CLPT is a small-cap name in its sector. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Market Cap
$454.3M
Beta
1.24
P/E (TTM)
—
P/E (Fwd)
-16.12
EPS (TTM)
$-1.00
EPS (Fwd)
$-0.94
ROE
-149.7%
ROA
-25.0%
Cash
$35.6M
Total Debt
$63.6M
Free CF
-$11.6M
52W Change
37.4%
Annual Financials
Cash vs Debt
On the balance sheet, CLPT has $35.6M in cash with $63.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$11.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -149.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $20.6M (2022) to $37.0M (2025), reflecting a 80% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ClearPoint Neuro, Inc.'s trajectory.